dorsaVi Limited ( (AU:DVL) ) has issued an announcement.
DorsaVi has completed a strategic analysis showing that integrating its EMG and movement sensors with resistive random-access memory and neuromorphic in-sensor computing could sharply reduce sensor counts and data loads in exoskeletons, while more than doubling battery life. By embedding decision-making capability directly into each sensor node, the company aims to deliver sub-30 millisecond response times and over 90% classification accuracy, enabling exoskeletons to respond to a user’s movement intent before motion is fully executed.
The company is targeting the sensing and decision-intelligence layer rather than building exoskeleton hardware, positioning itself as a technology partner to manufacturers with potential revenue from sensor sales, OEM integrations, licensing, validation services, and software. A staged deployment path, from eight sensors for full limb mapping to a streamlined five-sensor configuration for field use, is designed to support near-term adoption and extend the commercial relevance of its platform, as the global exoskeleton market is forecast to expand strongly across medical, industrial, defence, and aged care applications.
More about dorsaVi Limited
DorsaVi Limited is an Australian medical technology and sensing company focused on electromyography (EMG) and movement sensors for wearable robotics, rehabilitation, and human-motion analysis. The company is positioning its platform as an ultra-low power, in-sensor computing solution targeting the intelligence layer of exoskeletons and other assistive systems across healthcare, industrial, defence, and aged care markets.
Average Trading Volume: 2,147,727
Technical Sentiment Signal: Buy
Current Market Cap: A$45.98M
Find detailed analytics on DVL stock on TipRanks’ Stock Analysis page.